Introduction {#s1}
============

Blood vessel dysfunction in the retina is a critical component of several blinding eye diseases. In particular, the retina is sensitive to the fluid accumulation that can result from excessively leaking blood vessels in the eye and reduction of the ensuing edema is a therapeutic goal in the clinic ([@bib16]). Vascular endothelial growth factor A (VEGFA) is one of the key factors controlling endothelial cell biology in the eye ([@bib16]). The importance of VEGFA signaling is underscored by the clinical success of antibodies (bevacizumab, ranibizumab) neutralizing VEGFA, or soluble receptor fusion proteins (aflibercept), neutralizing several VEGF family members. These drugs preserve vision in many patients, but over time disease progression may resume, and for others there is no benefit even from the initial anti-VEGF treatment ([@bib9]). The role of VEGFA for survival of VEGFR2-expressing retinal neurons presents an additional challenge ([@bib45]). Moreover, anti-VEGF treatment has been linked to capillary loss and rarefaction of normal adult vasculature ([@bib31]). While a focus in the development of new therapies to treat retinopathies has been on increasing the potency of anti-VEGFA therapy, the detrimental effects of long-lasting VEGFA suppression are now being recognized ([@bib63]). Taken together, the development of alternative treatments to block excessive vascular leakage in the eye while sparing other VEGF functions is very important.

The retina is protected by a blood retinal barrier (BRB) which, under normal conditions, limits the extravasation of blood components into the tissue. The BRB consists of an inner barrier at the level of retinal vessels and an outer barrier at the cell junctions of the retinal pigment epithelium and it serves to stringently protect the tissue from pathogens, edema and inflammation ([@bib70]). The BRB is established in conjunction with vessel entry in the central nervous system during early development ([@bib13]). In eye diseases such as diabetic retinopathy, hypoxia and the ensuing increased production of VEGFA is accompanied by breakdown of the BRB ([@bib11]). The molecular mechanisms downstream of VEGFA leading to this disruption have not been defined.

VEGFA, originally identified as vascular permeability factor (VPF) ([@bib53]), binds to VEGFR2 inducing receptor phosphorylation and the propagation of signaling cascades regulating endothelial survival, proliferation and motility ([@bib56]). Acute responses to VEGFR2 activity include destabilization of endothelial junctions leading to increased permeability. Notably, phosphorylation of VEGFR2 at Y949 (951 in human) enhances permeability via the disruption of adherens junctions in the dermal vasculature, but also in pathologies such as neuroendocrine cancer, melanoma and glioblastoma ([@bib39]). Phosphorylation of Y949 creates a binding site for the adaptor molecule T cell specific adaptor (TSAd), which in turn binds c-Src at endothelial junctions ([@bib39]; [@bib43]; [@bib59]). c-Src is implicated in phosphorylation of vascular endothelial (VE)-cadherin ([@bib39]; [@bib1]; [@bib64]; [@bib65]). VE-cadherin is the main component of endothelial adherens junctions, forming homophilic interactions between endothelial cells, and is critical in regulation of permeability in response to VEGFA as well as inflammatory cytokines ([@bib39]; [@bib3]; [@bib36]). Tyrosine phosphorylation of VE-cadherin is associated with different biological functions. Thus, phosphorylation of Y658 and Y685 is associated with the control of vascular permeability ([@bib47]), and angiogenic sprouting ([@bib27]), and Y658 with junction stability ([@bib24]; [@bib52]), whereas phosphorylation of Y731 in VE-cadherin is linked to leukocyte extravasation ([@bib67]). Serine phosphorylation of VE-cadherin at S665 is also implicated in regulation of endothelial junctions ([@bib25]).

Here, the molecular mechanisms underlying vessel leakage in eye diseases were studied using mouse models deficient in the VEGFR2-TSAd-VE-cadherin pathway. Interruption of the VEGFR2 pY949F pathway resulted in suppressed vascular leakage at the choroid or at the superficial retinal vasculature in mouse models of age-related macular degeneration and diabetic retinopathy, respectively. Furthermore, disrupting this pathway correlated with reduced VE-cadherin pY685 levels and reduced pathological neoangiogenesis of the superficial retinal vasculature. These data identify VEGFR2 pY949 signaling as an important contributor to edema in retinopathies which may serve as a basis for development of new therapies selectively suppressing VEGFA-dependent disruption of the vascular barrier.

Results {#s2}
=======

Reduced vessel leakage from *Kdr^Y949F/Y949F^* retinopathy models {#s2-1}
-----------------------------------------------------------------

The *Vegfr2^Y949F/Y949F^* mouse (henceforth denoted *Kdr^Y949F/Y949F^*), lacks the pY949 phosphosite of VEGFR2 and therefore fails to induce activation of c-Src. We have previously shown that *Kdr^Y949F/Y949F^* exhibits suppressed vessel permeability in the dermis specifically in response to VEGFA ([@bib39]). The stringent BRB of the retinal vasculature is not expected to be regulated by VEGFA, however, in ocular disease such as retinopathy, the BRB may be broken down ([@bib62]); in accordance, proliferative retinopathies are characterized by increased transvessel flow and edema ([@bib11]; [@bib33]; [@bib42]; [@bib57]). We therefore set out to determine whether the pY949 signaling pathway regulates pathologic leakage in the setting of proliferative retinopathy.

To induce retinopathy, *Kdr^Y949F/Y949F^* mice and their wild-type littermates (henceforth referred to as *Kdr^+/+^*) were exposed to a laser-induced chorodial neovascularization (CNV) model. The vascular lesions established after laser pulse disruption of the Bruch's membrane mimic the progression of exudative age-related macular degeneration ([@bib34]). The lesions develop from the choroidal vessels over the course of several days as a consequence of hypoxia and elevated production of VEGFA ([@bib4]). Choroids of CNV-treated *Kdr^+/+^* and *Kdr^Y949F/Y949F^* mice were collected 14 days post-laser injury, a timepoint corresponding to a phase of completed neoangiogenesis and relative maturation of vessels lesions ([@bib4]). Before collection, vessel leakage from the lesions was examined by monitoring extravasation of circulating 100 nm fluorescent microspheres, a particle size selected as being the smallest that would not simply leak through fenestrated pores of the choroid ([@bib29]). After 2 min of circulation, the microspheres remaining in circulation were flushed away by cardiac perfusion and choroid tissue was collected, immunostained, and analyzed by confocal microscopy for lesion size and microsphere accumulation. Lesions were of equal size ([Figure 1A--B](#fig1){ref-type="fig"}; 42038 µm^2^ ± 2514, *Kdr^+/+^*; 44399 µm^2^ ± 3454, *Kdr^Y949F/Y949F^*), still, microsphere accumulation was significantly reduced in the vicinity of *Kdr^Y949F/Y949F^* lesions as compared to the *Kdr^+/+^* lesions ([Figure 1C--D](#fig1){ref-type="fig"}). We conclude that pathological leakage in the choroid can be suppressed by attenutation of pY949 VEGFR2 signaling and that this decrease is not simply due to an anti-angiogenic effect of interrupted VEGFA signaling.

![Reduced leakage from CNV lesions in *Kdr^Y949F/Y949F^* retinas at D14.\
(**A**) Representative CNV lesions imaged from whole mount choroid tissue, collected at day (**D**) 14 after laser injury, from *Kdr^Y949F/Y949F^* and *Kdr^+/+^* littermates, immunostained for isolectin B4 (IB4). Scale bar = 100 µm. Dotted red line highlights the extent of lesion formation. (**B**) Quantification of average lesion size at D14 after injury. n = 60--67 lesions per group from 9 to 11 mice per group. ns = not significant p=0.6882. (**C**) Representative images of D14 lesions from *Kdr^Y949F/Y949F^* and *Kdr^+/+^* littermates immunostained for IB4 (red), showing accumulation of tail-vein injected, fluorescent 100 nm microspheres (white) in the tissue around the lesions. Insets enlarged (right) with microspheres shown as black dots on white background. Scale bar = 100 µm. Inset scale bar = 25 µm. Arrows point to areas of microsphere accumulation. (**D**) Quantification of the average area of accumulated microspheres per image after 2 min of circulation. n = 35--74 lesions per group from 7 to 14 mice per group. \*\*\*p\<0.001 p=0.0006.\
Figure 1---source data 1.Text file containing the ImageJ macro code used to quantify microsphere accumulation in CNV experiments.\
Figure 1---source data 2.Excel file containing the collected CNV lesion size and microsphere area.](elife-54056-fig1){#fig1}

To extend this finding we applied another common retinopathy model, oxygen-induced retinopathy (OIR). In the OIR model, mice are exposed to 75% oxygen during postnatal (P) days 7--12 after which they are returned to normal atmosphere (21% oxygen). During the first stage, VEGFA expression is suppressed which leads to apoptosis of capillaries in the central region of the retina ([@bib37]). In the second stage, retinal VEGFA expression is induced as a consequence of moving mice from high oxygen to normal atmosphere (relative hypoxia), leading to the formation of pathological neovascular tufts, characterized by being disorganized and leaky ([@bib14]). To determine the role of VEGFR2 pY949 signaling in regulating leakage from neovascular tufts, 25 nm fluorescent microspheres, a particle size chosen as the smallest commercially available, were injected in the tail vein of P17 pups, and allowed to circulate for 15 min before the remaining microspheres were flushed away by cardiac perfusion.

As expected, retinas from P17 *Kdr^+/+^* pups submitted to OIR had a considerable central avascular region remaining following the early phase of vessel destruction and also abundant retinal neovascular tuft formation. Of note, at P17, *Kdr^Y949F/Y949F^* mice had a reduction in tuft formation compared to the *Kdr^+/+^* mice ([Figure 2A--C](#fig2){ref-type="fig"}; see [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"} for images without overlay). This was not due to differences in body weight of P17 pups ([Table 1](#table1){ref-type="table"}). The reduced tuft formation was a result of suppressed pathological angiogenesis during the P12-17 period when mice were kept in normal atmosphere following the hyperoxia period. At P12, the morphology of the retina vasculature was similar for *Kdr^Y949F/Y949F^* and *Kdr^+/+^* littermates ([Figure 2---figure supplement 1B--C](#fig2s1){ref-type="fig"}).

![Reduced leakage from OIR lesions in *Kdr^Y949F/Y949F^* retinas at P17.\
(**A**) Representative images of whole mount retinas from *Kdr^Y949F/Y949F^* and *Kdr^+/+^* mice, collected on postnatal day (P)17 after OIR challenge, stained with isolectin B4 (IB4). Avascular tissue in the central retina is marked with purple overlay and neovascular tufts, clusters of disordered vessels, are indicated with blue overlay in the insets. See [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"} for corresponding images without color overlays. Scale bar = 500 µm. Inset scale bar = 100 µm. (**B**) Neovascular tuft coverage as percentage of total retina area. (**C**) Avascular area as percentage of total retina area. n = 10--14 mice, mean value of both eyes;\*\*\*, p\<0.00 p=0.003; ns, not significant p=0.0775. (**D**) Representative images of tufts from *Kdr^Y949F/Y949F^* and *Kdr^+/+^* mice immunostained for isolectin B4 (IB4;red), showing accumulation of tail-vein injected green-fluorescent 25 nm microspheres (white) in the tissue around the tufts. Insets enlarged (right) with microspheres shown as black dots on white background. Scale bar = 25 µm. Inset scale bar = 10 µm. Dotted line representing the region of IB4 staining. Arrows point to accumulated microspheres; red arrows for microspheres within the IB4 positive region, blue arrows for microspheres away from the vessel wall. (**E**) Quantification of D, showing average area of accumulated extravasated microspheres, normalized to tuft area, per image after 15 min of circulation. n = 6--7 mice per group, 3--11 images per mouse; \*\*p\<0.01 p=0.0033.\
Figure 2---source data 1.Text file containing the ImageJ macro code used to quantify microsphere accumulation in OIR experiments.\
Figure 2---source data 2.Excel file containing the collected *Kdr* tuft area, avascular area, and extravasated microsphere area.](elife-54056-fig2){#fig2}

###### Body weight at P17 of mice subjected to OIR.

Table 1---source data 1.Excel file containing the bodyweight information for individual mice used in OIR experiments.

  --------------------------------------------------
  Mouse strain/genotype               Body weight\
                                      (+ / - SD)
  ----------------------------------- --------------
  *Kdr^+/+^*                          6.53 (0.94)

  *Kdr^Y949F/Y949F^*                  6.86 (0.65)

  *Sh2d2a^iECWT^*                     5.75 (0.76)

  *Sh2d2a^iECKO^*                     5.68 (1.02)

  VEC-Y685F -- wildtype littermates   6.49 (1.02)

  VEC-Y685F                           6.37 (1.02)

  VEC-WT -- wildtype littermates      5.83 (0.76)

  VEC-WT                              5.94 (0.92)
  --------------------------------------------------

Importantly, extravascular accumulation of microspheres in regions of neovascular tuft growth was significantly suppressed in *Kdr^Y949F/Y949F^* retinas compared to *Kdr^+/+^* ([Figure 2D--E](#fig2){ref-type="fig"}). Note that vessel-proximal microspheres, sticking to the either side of the wall of the disorganized tufts, were not included in the quantification. We conclude that disrupting pY949 signaling during OIR leads to a suppression of pathological vessel leakage and also to a reduction in pathological neoangiogenesis. The decrease in tuft formation in itself results in reduced overall leakage, however, it should be noted that remaining tufts leaked less in OIR-challenged *Kdr^Y949F/Y949F^* mice ([Figure 2E](#fig2){ref-type="fig"}). Moreover, the extent of infiltration of inflammatory CD68+ and CD45+ cells were similar at P17 for the *Kdr^Y949F/Y949F^* and *Kdr^+/+^* strains indicating that the enhanced barrier in the *Kdr^Y949F/Y949F^* pups was specific for macromolecules and did not exclude inflammatory cells ([Figure 2---figure supplement 2A--C](#fig2s2){ref-type="fig"}).

pY949 signaling axis results in altered VE-cadherin phosphorylation {#s2-2}
-------------------------------------------------------------------

The canonical signalling pathway downstream of the pY949 phosphosite consists of the Src Homology 2 (SH2) containing adaptor-protein TSAd (gene designation *Sh2d2a*), which binds to pY949 with high affinity. TSAd in turn recruits c-Src, leading to the phosphorylation of VE-cadherin (illustrated in [Figure 3A](#fig3){ref-type="fig"}; [@bib39]; [@bib59]). To assess the role of these downstream players in retinopathy, we expanded our studies using mice treated with tamoxifen at P12 to specifically delete TSAd expression in endothelial cells, *Sh2d2a^fl/fl^; Cdh5-CreERT2* (denoted *Sh2d2a ^iECKO^)*. After OIR challenge of *Sh2d2a^iECKO^* mice along with their wild-type littermates (*Sh2d2a^fl/fl^;* referred to as *Sh2d2a^iECWT^),* tuft formation was reduced in *Sh2d2a ^iECKO^* mice to a similar extent as seen with *Kdr^Y949F/Y949F^* mice ([Figure 3B--C](#fig3){ref-type="fig"}: see [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"} for images without overlay) while the avascular area was similar in the *Sh2d2a^iECKO^* and *Sh2d2a^iECWT^* mice at P17 ([Figure 3D](#fig3){ref-type="fig"}). Cre recombination in the *Sh2d2a^iECKO^* model was approximately 80% as assessed by vessel area ([Figure 3---figure supplement 1B,C](#fig3s1){ref-type="fig"}), in agreement with immunoblotting analysis performed earlier to show the efficiency of *Sh2d2a* excision in this model ([@bib27]). The distribution of recombined endothelial cells was similar between neoangiogenic tufts and the normal vasculature.

![pY949 signaling axis involvement in retinopathy pathology.\
(**A**) Graphic representation of VEGFR2 signaling cascade initiated by Y949 phosphorylation. (**B**) Representative images of whole mount retinas from *Sh2d2a^iECKO^* and *Sh2d2a^iECWT^* mice, collected on postnatal day (P)17 after OIR challenge, stained with isolectin B4 (IB4) with green color marking GFP-positive cells indicating TSAd-deficiency. Avascular area shown with purple overlay, neovascular tufts shown as blue overlay in inset. Scale bar = 500 µm. Inset scale bar = 100 µm. (**C**) Neovascular tuft coverage as percentage of total retina area. (**D**) Avascular area as percentage of total retina area. n = 10--15 mice, mean value of both eyes \*\*\*, p\<0.001 p=0.0001; ns, not significant p=0.3680 E) Representative maximum intensity projections of tufts from *Kdr^Y949F/Y949F^* and *Kdr^+/+^* mice immunostained for isolectin B4 (IB4; white), VE-cadherin (green), and pY418 c-Src (magenta). Scale bar = 25 µm. (**F**) Quantification shows percentage tuft junctional area, as defined by VE-cadherin immunostaining, positive for pY418 c-Src. n = 7--8 retinas from four mice per group; mean value from four images per retina ns = not significant p=0.6334. (**G--H**) Representative maximum intensity projections of tufts from *Kdr^Y949F/Y949F^* and *Kdr^+/+^*, as well as non-tuft regions from *Kdr^+/+^* retinas immunostained for VE-cadherin (green) and G) VE-cadherin pY658 (red) or H) for VE-cadherin pY685 (red). (**I**) Quantification of percentage pY658 immunostaining in tufts, in relation to total tuft junctional (VE-cadherin) area. (**J**) Quantification of percentage pY685 immunostaining as in I. Scale bars in G, H = 50 µm. Inset scale bar = 10 µm. n = 4--6 mice, one retina per mouse, from three independent experiments, 5--9 images per group. ns, not significant p=0.4845, \*\*p\<0.01 p=0.0086.\
Figure 3---source data 1.Excel file containing *Sh2d2a* OIR tuft and avascular area, *Kdr* junctional pSrc, and *Kdr* VE-cadherin phosphorylation area.](elife-54056-fig3){#fig3}

The cytoplasmic tyrosine kinase c-Src phosphorylates VE-cadherin in vitro ([@bib1]; [@bib47]) and its activity correlates with detection of phosphorylated VE-cadherin in vivo ([@bib47]). Immunostaining for pY418, a tyrosine residue in c-Src kinase domain required for maximal kinase activity, revealed active c-Src at the periphery of the retina and elevated levels in the neovascular tufts of *Kdr^Y949F/Y949F^* and *Kdr^+/+^* mice ([Figure 3E](#fig3){ref-type="fig"}). Of interest, some pY418 c-Src immunostaining was localized at cell-cell junctions as indicated by co-staining with VE-cadherin. Notably, the level of junctional pY418 c-Src was similar in tufts from *Kdr^Y949F/Y949F^* and *Kdr^+/+^* mice ([Figure 3F](#fig3){ref-type="fig"}), indicating that pY949 signaling does not account for c-Src activity at cell-cell junctions in this model. Thus, signaling through pY949 in VEGFR2 appeared not to contribute to regulation of c-Src kinase activity at endothelial junctions in the retina vasculature.

As VE-cadherin is the major component of adherens junctions and thus vital for vessel integrity ([@bib26]), we performed immunostaining of P17 *Kdr^Y949F/Y949F^* and *Kdr^+/+^* retinas after OIR, to examine VE-cadherin expression and junction morphology. Neovascular tufts exhibited junctions with an irregular VE-cadherin morphology compared to non-tuft regions ([Figure 3G,H](#fig3){ref-type="fig"}, compare VE-cadherin morphology in tuft and non-tuft panels showing *Kdr^+/+^*), suggestive of increased internalization and degradation of VE-cadherin in the tufts ([@bib8]; [@bib17]). In agreement, tuft endothelial junctions were detected by antibodies against two known phosphorylation sites in VE-cadherin, pY658 and pY685 ([Figure 3G,H](#fig3){ref-type="fig"}), associated with VE-cadherin turnover ([@bib47]). The level of pY658 immunostaining was similar between *Kdr^Y949F/Y949F^* and *Kdr^+/+^* tufts ([Figure 3I](#fig3){ref-type="fig"}). In contrast, pY685 levels were significantly lower in the *Kdr^Y949F/Y949F^* retinal tufts compared to *Kdr^+/+^* ([Figure 3J](#fig3){ref-type="fig"}).

The underlying vascular plexus showed positive immunostaining with the VE-cadherin phosphoantibodies as well, though to a lesser degree ([Figure 3G,H](#fig3){ref-type="fig"}). Arteries throughout the retina, including in the neovascularized regions, essentially lacked immunostaining for pY685 and pY658 ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}), in keeping with previous findings on the lack of arterial VE-cadherin phosphorylation at these residues ([@bib47]).

Involvement of VE-cadherin pY685 in lesion formation and vessel leakage {#s2-3}
-----------------------------------------------------------------------

To corroborate the role of pY685 VE-cadherin in VEGFR2-regulated neovascular lesion formation, we performed immunostaining for VE-cadherin and pY685 VE-cadherin on choroid tissue from *Kdr^Y949F/Y949F^* and *Kdr^+/+^* mice after CNV. Lesions at D14 displayed pY685 VE-cadherin immunostaining, though the intensity of the pY685 signal was significantly lower in the *Kdr^Y949F/Y949F^* lesions ([Figure 4A,B](#fig4){ref-type="fig"}). This result suggests that junctional VE-cadherin phosphorylation at Y685 is dependent on pY949 VEGFR2 signaling also in the choroid vasculature.

![Involvement of VE-cadherin pY685 in lesion formation and vessel leakage.\
(**A**) Representative CNV lesions imaged from whole mount choroid tissue, collected at D14 from *Kdr^Y949F/Y949F^* and *Kdr^+/+^* littermates, immunostained for VE-cadherin (green), pY685 (magenta) and isolectin B4 (IB4; white). Scale bar = 100 µm; dotted red line highlights the extent of lesion formation in the IB4 channel. (**B**) Quantification of junctional pY685 immunostaining in the lesions. Junctional intensity expressed as the fold reduction of intensity as compared to the average *Kdr^+/+^* lesion intensity. n = 14--28 lesions per group from 3 to 5 mice per group, \*\*p\<0.01 p=0.0071. (**C**) Whole mount retinas from VEC-Y685F mice and VEC-WT mice, collected on P17 after OIR challenge, stained for IB4. Avascular area shown with purple overlay, neovascular tufts shown as blue overlay in inset. Scale bar = 500 µm. Inset scale bar = 100 µm. (**D**) Tuft coverage and E) avascular area. n = 8--11 mice per group, average of two retinas per mouse. \*\*p\<0.05 p=0.0012; ns = not significant, p=0.1535. (**F**) Representative images of accumulation of 25 nm green-fluorescent microspheres (white) in VEC-Y685F and VEC-WT control mice stained for isolectin B4 (IB4; red), showing accumulation in the tissue around the tufts. Insets enlarged (right) with microspheres shown as black dots on white background. Scale bar = 25 µm. Inset scale bar = 10 µm. Dotted line representing the region of IB4 staining. Arrows point to accumulated microspheres; red arrows for microspheres within the IB4 positive region, blue arrows for microspheres away from the vessel wall. (**G**) Quantification of F showing average area of accumulated extravasated microspheres, normalized to tuft area, per image after 15 min of circulation. n = 5--7 mice per group; 10--18 images per mouse \*\*p\<0.01, p=0.0016.\
Figure 4---source data 1.Excel file containing collected VE-cadherin pY685 staining in *Kdr* CNV lesions, VEC-Y685 tuft and avascular area, and VEC-Y685 extravasated microsphere area.](elife-54056-fig4){#fig4}

The importance of VE-cadherin Y685 phosphorylation in the development of retinopathy was further demonstrated using a VE-cadherin Y685F mutant mouse model and its corresponding wild-type construct (VEC-Y685F and VEC-WT, respectively) ([@bib67]), in the OIR model. In these strains, wild-type and mutant *CDH5* cDNA is introduced, replacing the endogenous mouse *Cdh5* gene. The two strains were maintained separately and each therefore had their separate C57Bl/6 wild-type littermates carrying the intact mouse *Cdh5* gene. The extent of oxygen-induced neovascular tuft formation as well as the avascular area in VEC-WT P17 mice was indistinguishable from wild-type C57Bl/6 littermates ([Figure 4---figure supplement 1A--C](#fig4s1){ref-type="fig"}) and the avascular area at P12 was likewise indistinguishable for these strains ([Figure 4---figure supplement 1D--E](#fig4s1){ref-type="fig"}). At P17, however, tuft formation was reduced in the VEC-Y685F pups compared to VEC-WT controls ([Figure 4C--D](#fig4){ref-type="fig"}), to a similar extent as seen for the *Kdr^Y949F/Y949F^* and *Sh2d2a^iECKO^* strains in relation to their respective controls ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). As for the *Kdr^Y949F/Y949F^* and *Sh2d2a^iECKO^* strains strains, the avascular area after high oxygen-exposure was equivalent between VEC-Y685F and VEC-WT mice ([Figure 4E](#fig4){ref-type="fig"}).

Immunostaining with the anti-VE-cadherin phosphoantibodies revealed complete loss of pY685 immunostaining in the VEC-Y685F retinas, validating the specificity of the antibody ([Figure 4---figure supplement 1F](#fig4s1){ref-type="fig"}). There was no difference in the levels of total VE-cadherin or VE-cadherin pY658 detected by immunostaining, in the VEC-Y685F tufts compared to WT ([Figure 4---figure supplement 1F](#fig4s1){ref-type="fig"}). Neovascular tuft leakage following OIR was examined following the same protocol as above. Microsphere accumulation was significantly reduced in the tufts of VEC-Y685F mice following OIR, compared to VEC-WT ([Figure 4G--H](#fig4){ref-type="fig"}). As a control, microsphere leakage was assessed in VEC-WT and littermate C57Bl/6 P17 mice after OIR, which showed no difference in extravascular accumulation ([Figure 4---figure supplement 1G--H](#fig4s1){ref-type="fig"}). Combined, these data show an essential role for VEGFR2 and downstream VE-cadherin Y685 phosphorylation in elevated vascular leakage in retinopathies.

Discussion {#s3}
==========

Here we demonstrate that blocking VEGFA-induced VEGFR2 pY949 signaling at any of several steps in the downstream pathway, leads to reduced vascular leakage in two independent retinopathy models, OIR and CNV. While exposure to high oxygen in the OIR procedure causes pathological vascularization in the superficial retinal vessels, the CNV laser injury targets the choroidal vasculature. Thus, we implicate VEGFR2 pY949 signaling in exaggerated vascular leakage in two very different vascular beds in the retina.

Importantly, we identify components of a signaling axis that can be targeted in order to control excessive vascular leakage and pathological neoangiogenesis without interfering with physiological functions of VEGFA. Although pathological vascular tuft formation was diminished in the *Kdr^Y949F/Y949F^* strain, careful characterization of the vasculature in different organs of this strain has not revealed deficiencies in vessel density or morphology during development ([@bib39]). Of note, the improved barrier properties in the *Kdr^Y949F/Y949F^* vasculature do not exclude infiltration of CD68/CD45+ inflammatory cells ([@bib39] and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). The effect of bacterial infections and wound healing properties remain to be tested. Nevertheless, based on the currently available information, we favor the notion that suppressed macromolecular leakage in response to VEGFA plays an important role in pathologies while it is dispensable in physiology. We do not exclude that leakage suppression to some extent interferes with neoangiogenesis due to the lack of a fibrinogen mesh for the new vessel to grow on [@bib18]. However, as leakage was suppressed in the *Kdr^Y949F/Y949F^* retinas in both the CNV and OIR (normalized to neovascular area) models, our data support the concept that leakage is regulated separately from angiogenesis per se. We conclude that in a range of tissues, either in the CNS or in peripheral organs, the VEGFR2 -- TSAd -- VE-cadherin pathway regulates vascular leakage in the context of disease, independent of angiogenesis.

A considerable strength of our study is in the use of intravenously injected microspheres to assess leakage, as we are able to address both pathological vessel growth and leakage simultaneously. This is superior to traditional methodologies using Evans blue injection, to determine the area of dye leakage over the retina surface, or measure the relative amount of dye extracted from retinas using formamide ([@bib68]). Unlike the methodology described here, neither of these methods allow for the precise visualization of the leakage or how it relates to vessel morphology.

Studies in rodent models have suggested that a complete loss of VEGFA-induced signaling in the eye can lead to atrophy of the neural layers, which mechanistically can be explained by the presence of VEGFR2 on retinal neurons ([@bib46]; [@bib51]). In rats, anti-VEGFA treatment does not lead to damage of neural cells or loss of photoreceptor function ([@bib41]), indicating that VEGFA might indeed be dispensable for the neural retina in this species. However, retrospective and long term follow-up studies in human patients treated with anti-VEGFA therapies do provide examples of rare negative side effects such as hemorrhages, potentially linked to a systemic reduction of VEGFA ([@bib5]; [@bib20]; [@bib32]). Furthermore, anti-VEGFA treatment may contribute to the progression of geographic atrophy due to insufficient vascularization or to the fact that VEGFA may serve as a vital survival factor for the retinal pigment epithelium (RPE) ([@bib10]). Increased treatment frequency in patients receiving ranibizumab or bevacizumab is associated with greater loss of RPE, indicating geographic atrophy ([@bib19]; [@bib28]; [@bib50]). The necessity of repeated intraocular injections ([@bib48]) for the administration of current anti-VEGFA therapy reduces patient compliance ([@bib49]) and results in rare but serious instances of eye damage caused by the injection procedure, such as endophthalmitis or retinal detachment ([@bib20]; [@bib40]). Ultimately, the interaction between VEGFR2 pY949/pY951 and TSAd would be an ideal target to specifically block leakage but save other aspects of VEGFR2 biology.

The literature strongly implicates Src family kinases (SFK) in the phosphorylation of tyrosine residues on VE-cadherin, thereby playing an essential role in controlling vessel permeability ([@bib1]; [@bib47]; [@bib67]; [@bib61]). In the context of OIR, direct inhibition of c-Src activation by kinase inhibitors ([@bib54]; [@bib66]), indirect inhibition of c-Src kinase ([@bib60]), or suppressed c-Src expression using siRNA ([@bib69]), all result in decreased tuft formation. Here, we found that neovascular tufts displayed abundant pY418 c-Src at endothelial junctions. Although we may have expected decreased p418 c-Src levels in the *Kdr^Y949F/Y949F^* tufts, the levels were similar in the mutant and *Kdr^+/+^* littermates. These data indicate that while activation of c-Src alone may be required for induction of permeability and tuft formation, it may not be sufficient to induce these events. In agreement, a triggering event, in addition to c-Src activity, is needed for opening of paracellular junctions ([@bib1]; [@bib2]). Also, Orsenigo and coworkers detected constitutive, flow-dependent pY418 c-Src in leakage-permissive venules, but described an additional triggering event required for leakage to become established ([@bib47]). Our data suggests the scenario that VEGFR2 pY949 signaling leads to close proximity and complex formation between VEGFR2 and VE-cadherin potentially involving c-Src ([@bib39]), which may be activated in a VEGFR2-independent manner. A caveat in the interpretation of these data is that the pY418 antibody used to detect activated c-Src may cross-react with the related Yes and Fyn antibodies. Currently, reagents specifically recognizing only c-Src are missing.

The acute stimulation of blood vessels with bradykinin or histamine to induce leakage is linked to a strong and transient drop in VE-cadherin phosphorylation due to internalization and degradation ([@bib47]). We find that in the chronic disease models studied here, regions of greater VE-cadherin phosphorylation displayed increased leakage. The decrease in leakage observed in the *Kdr^Y949F/Y949F^* mice challenged with OIR or CNV, correlated with a reduction in VE-cadherin pY685 immunostaining, identifying this phosphosite as a key mediator in leakage regulation. This finding is in line with the observation that sites of leakage in a cremaster model correlated with staining for VE-cadherin pY685 ([@bib67]). The mechanism underlying the important role of VE-cadherin pY685 compared to pY658 in vascular permeability is not understood. The pY685 phosphosite serves as the binding site for C-terminal Src Kinase (CSK), a negative regulator of c-Src activity. CSK phosphorylates c-Src at pY527, leading to its inactivation ([@bib38]). Reduced pY685 VE-cadherin levels, as seen in the *Kdr^Y949F/Y949F^* mice, would predict less CSK at the junction and ultimately increased c-Src activity ([@bib7]; [@bib30]), which we did not observe. Moreover, CSK deletion in vitro does not alter barrier properties ([@bib1]). Another important aspect of the role of VE-cadherin pY685 is its regulation of pathological angiogenesis. Notably, tuft area was decreased per se, in the VEC-Y685F mutant ([Figure 3B,C](#fig3){ref-type="fig"}). VE-cadherin has been implicated in regulation of VEGFR2 signaling by limiting receptor internalization. In the presence of VE-cadherin, VEGFR2 is dephosphorylated by density-enhanced phosphatase (DEP)1, thus decreasing the levels of active VEGFR2 and proliferative signaling ([@bib35]). We hypothesize that VE-cadherin pY685 downstream effectors are critical in VEGFR2 signaling at junctions.

The VE-cadherin Y658 site has also been identified as an integral regulator of junctional stability. Phosphorylation of the site acts to displace bound p120 catenin leading to destabilized adherens junctions ([@bib24]; [@bib52]). VE-cadherin Y658 is phosphorylated by Src family kinases, with low levels of shear stress leading to maximal pY658 immunostaining ([@bib47]; [@bib15]). In the OIR model, tufts are known to have perturbed perfusion, which may drive the high pY658 intensity in tufts, to a similar extent in the WT and mutant models, as observed in this study.

At this point, VEGFA-targeting is the only pharmacological strategy exploited clinically and it is therefore of particular interest to understand how edema is established in response to VEGFA. Other molecular regulators of pathological leakage have been described that may operate in concert with or independently of the VEGFR2 Y949 signaling. Semaphorin 3A ([@bib12]), Neuropilin 1 ([@bib21]), activin-like kinase receptor type I ([@bib3]), angiopoietin-like 4 ([@bib6]), VE-PTP and Tie2 ([@bib22]; [@bib55]) have all been implicated in the control of junctional integrity in different vascular beds. Here, we provide information on the specific VEGFR2 signaling pathway leading to edema that can be tested as a readout in other systems. We also present an effective methodology to quantify leakage in relation to pathological angiogenesis, which we foresee will aid in exploration of new targets to treat retinopathies.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                Designation                                           Source or reference                                                             Identifiers                                                            Additional\
  (species) or resource                                                                                                                                                                                                                                     information
  -------------------------------------------- ----------------------------------------------------- ------------------------------------------------------------------------------- ---------------------------------------------------------------------- --------------------
  Strain, strain background (*Mus musculus*)   *Kdr^Y949F/Y949F^*                                    DOI: [10.1038/ncomms11017](http://dx.doi.org/10.1038/ncomms11017)                                                                                      C57Bl/6 background

  Strain; strain background (*Mus musculus*)   *Sh2d2a^fl/fl^; Cdh5-CreERT2*                         DOI: [10.1126/scisignal.aad9256](http://dx.doi.org/10.1126/scisignal.aad9256)                                                                          C57Bl/6 background

  Strain; strain background (*Mus musculus*)   *mT/mG*                                               DOI:\                                                                                                                                                  C57Bl/6 background
                                                                                                     [10.1002/dvg.20335](http://dx.doi.org/10.1002/dvg.20335)                                                                                               

  Strain; strain background (*Mus musculus*)   VEC-Y685F                                             DOI: [10.1038/ni.2824](http://dx.doi.org/10.1038/ni.2824)                                                                                              C57Bl/6 background

  Strain; strain background (*Mus musculus*)   VEC-WT                                                DOI: [10.1038/ni.2824](http://dx.doi.org/10.1038/ni.2824)                                                                                              C57Bl/6 background

  Antibody                                     Rat anti-VE-cadherin                                  BD Biosciences                                                                  Catalogue no: 555289\                                                  (1:100)
                                                                                                                                                                                     RRID:[AB_395707](https://scicrunch.org/resolver/AB_395707)             

  Antibody                                     Rabbit anti-VE-cadherin pY658                         DOI: [10.1038/ncomms2199](http://dx.doi.org/10.1038/ncomms2199)                                                                                        (1:50)

  Antibody                                     Rabbit anti-VE-cadherin pY688                         DOI: [10.1038/ncomms2199](http://dx.doi.org/10.1038/ncomms2199)                                                                                        (1:50)

  Antibody                                     Rabbit anti-phospho-Src (Tyr418)                      Thermo Fisher Scientific                                                        Catalogue no:\                                                         (1:100)
                                                                                                                                                                                     44--660G\                                                              
                                                                                                                                                                                     RRID:[AB_1500523](https://scicrunch.org/resolver/AB_1500523)           

  Antibody                                     Goat anti-CD45                                        BD Biosciences                                                                  Catalogue no: 553076\                                                  (1:300)
                                                                                                                                                                                     RRID:[AB_394606](https://scicrunch.org/resolver/AB_394606)             

  Antibody                                     Rat anti-CD68                                         BioRad Laboratories                                                             Catalogue no: MCA1957\                                                 (1:300)
                                                                                                                                                                                     RRID:[AB_322219](https://scicrunch.org/resolver/AB_322219)             

  Antibody                                     Donkey anti-Rat                                       Thermo Fisher\                                                                  Catalogue no:\                                                         (1:500)
                                                                                                     Scientific                                                                      A-21208\                                                               
                                                                                                                                                                                     RRID:[AB_141709](https://scicrunch.org/resolver/AB_141709)             

  Antibody                                     Donkey anti-Rabbit                                    Thermo Fisher Scientific                                                        Catalogue no:\                                                         (1:500)
                                                                                                                                                                                     A-31572\                                                               
                                                                                                                                                                                     RRID:[AB_162543](https://scicrunch.org/resolver/AB_162543)             

  Antibody                                     Donkey anti-Goat                                      Thermo Fisher Scientific                                                        Catalogue no:\                                                         (1:500)
                                                                                                                                                                                     A-21432 RRID:[AB_2535853](https://scicrunch.org/resolver/AB_2535853)   

  Software                                     ImageJ                                                NIH, Bethesda,\                                                                 RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)           
                                                                                                     MD, USA                                                                                                                                                

  Software                                     GraphPad Prism                                        GraphPad                                                                        RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)           

  Other                                        Alexa Fluor 488-Isolectin B4                          Thermo Fisher Scientific                                                        Catalogue no I21411\                                                   (1:500)
                                                                                                                                                                                     RRID:[AB_2314662](https://scicrunch.org/resolver/AB_2314662)           

  Other                                        Alexa Fluor 594-Isolectin B4                          Thermo Fisher Scientific                                                        Cataolgue no: I21413\                                                  (1:500)
                                                                                                                                                                                     RRID:[AB_2313921](https://scicrunch.org/resolver/AB_2313921)           

  Other                                        Alexa Fluor 647-Isolectin B4                          Thermo Fisher Scientific                                                        Catalogue no: I32450\                                                  (1:500)
                                                                                                                                                                                     RRID:[SCR_014365](https://scicrunch.org/resolver/SCR_014365)           

  Other                                        Fluoro-Max Dyed Blue Aqueous Fluorescent Particles    Thermo Fisher Scientific                                                        Catalogue no: B0100                                                    

  Other                                        Fluoro-Max Dyed Green Aqueous Fluorescent Particles   Thermo Fisher Scientific                                                        Catalogue no: G25                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animal studies {#s4-1}
--------------

Mouse husbandry and oxygen-induced retinopathy (OIR) challenge took place at Uppsala University, and the University board of animal experimentation approved all animal work for those studies. Choroidal neovascularization (CNV) experiments took place at Karolinska Institutet, St. Erik Eye Hospital, Stockholm; the procedures were approved by the Stockholm's Committee for Ethical Animal Research. Animal handling was in accordance to the ARVO statement for the Use of Animals in Ophthalmologic and Vision Research. All animal experiments were repeated at least three independent times with wildtype and mutant mice compared within the same litter when possible. Sample size was chosen to ensure reproducibility and allow stringent statistical analysis. Randomization of mice and blinding of the investigators were not performed. No mice were excluded from analyses, though CNV lesions that fused with neighboring lesions were excluded from analysis.

A knock-in mutation in the VEGFR2 gene, *Kdr*, was created by homologous recombination using VelociGene technology (Regeneron Pharmaceuticals, New York, USA), wherein the tyrosine (Y) at position 949 was replaced with phenylalanine (F) ([@bib39]). The *Kdr^Y949F/Y949F^* mice, initially on mixed 129S6/C57BL/6 background, were extensively backcrossed to C57BL/6J (Taconic Biosciences). *Sh2d2a^fl/fl^; Cdh5-CreERT2* mice, referred to as inducible Endothelial Cell-specific Knock Out *Sh2d2a^iECKO^* mice (previously denoted *Tsad^iECKO^* mice), were generated as described ([@bib27]). Inducible deletion was by intraperitoneal injection of tamoxifen (Sigma, T5648) at P12, upon removal from hypoxia, and 24 hr later at P13 (400 µg/dose). To track recombination, the *Sh2d2a^iECKO^* strain was crossed with the *mT/mG* strain (JAX stock \#007676). Cre-driven recombination resulted in *mTmG*-dependent conversion to green fluorescent protein (GFP) ([@bib44]). VE-cadherin (VEC)-Y685F and VEC-WT mice were generated using either WT or Y685F mutant human *CDH5* (VE-cadherin gene designation) cDNA to replace the endogenous mouse *Cdh5* gene ([@bib67]).

OIR {#s4-2}
---

A standard OIR model was used as described with minor modification ([@bib14]). Briefly, each litter of pups was placed, along with the mother, into a chamber that maintained an oxygen concentration of 75.0% (ProOx 110 sensor and A-Chamber, Biospherix, Parish, NY). Mice remained in the chamber for 5 days, beginning at P7 and extending until P12, when they were returned to normal atmosphere (\~21% oxygen) until termination at P17. While the pups remained at 75% oxygen throughout, lactating adult females were removed from the chamber on P8, P9, P10, and P11 for 2 hr a day, to prevent oxygen toxicity-related death. At P17, pups were weighed and sacrificed and eyes enucleated and fixed in 4% paraformaldehyde (PFA) at room temperature for 30 min. For microsphere extravasation experiments, mice at P17 were briefly warmed under a heat lamp to dilate tail veins before a tail vein-injection of microspheres (1% solution of 25 nm green fluorescent polystyrene beads; 50 µl per mouse (ThermoFisher Cat.no. G25). Microsphere size was chosen based on previous experience in analyzing VEGFA-regulated leakage from non-fenestrated vessels ([@bib39]). Microspheres were allowed to circulate for 15 min before final sacrifice and tissue collection. To remove blood and microspheres from the retinal vessels, mice were perfused with phosphate-buffered saline (PBS). Mice were fully anesthetized using isofluorane inhalation or alternately by an intraperitoneal injection of a mixture of ketamine/xylazine (100 mg/kg ketamine; 20 mg/kg xylazine), after which room temperature PBS was flushed through the vasculature. Litters of mice exposed to OIR protocol were excluded from analysis when the average weight of pups at P17 was less than 5.5 grams, as low weight may indicate maternal neglect or other reasons for inability to thrive ([@bib58]). See [Table 1](#table1){ref-type="table"} for average weight of pups at P17.

CNV {#s4-3}
---

A standard protocol of laser-induced CNV was employed ([@bib34]; [@bib4]). Briefly, 6--14 week-old *Kdr^Y949F/Y949F^* mice were anesthetized (ketamine/xylazine; 30 mg/kg, 5 mg/kg respectively) and pupils dilated using a topical administration of tropicamide (0.5%; Alcon, Puurs, Belgium). Choroidal neovascularization lesions were induced in both eyes by diode laser (532 nm; IRIS Medical, Mountain View, CA, USA) with settings: 75 µm spot, 200 mW intensity, 100 ms duration. All visual hemorrhagic lesions were excluded from the study. After laser-induction, animals were treated twice with 1 mL of saline (9 mg/mL NaCl; B. Braun, Melsungen, Germany) subcutaneously under the back skin to prevent dehydration and the eyes were kept lubricated by topical administration of a paraffin and Vaseline mix (APL, Gothenburg, Sweden). At post-laser day 8, or 14, mice were culled and eyes immediately enucleated. The retina tissue was carefully dissected away to expose the choroid and CNV lesions. At day 14, prior to sacrifice, mice were warmed on heating pads and given a tail vein-injection of microspheres (1% solution of 100 nm Blue-fluorescent polystyrene beads; 100 µl per mouse (ThermoFisher Cat.no. B100) followed by 2 min of circulation and perfusion with fixative via cardiac puncture under isoflurane anesthesia. A larger microsphere size (100 nm) was chosen than for the OIR analyses (25 nm) to avoid spontaneous passage of small microspheres through the fenestrated choroidal vasculature. When the CNV lesions created in one eye grew and fused together, all fused lesions were excluded from further analysis.

Antibodies {#s4-4}
----------

Retinal vasculature and CNV lesions were immunostained with directly conjugated Alexa Fluor 488-Isolectin B4, Alexa Fluor 594-Isolectin B4, or Alexa Fluor 647-Isolectin B4 (Sigma). Endothelial cell junctions and phosphorylated VE-cadherin were stained with anti-VE-cadherin antibody (1:100; BD Rat 555289) and affinity purified rabbit antibodies against VE-cadherin pY658 and pY685 ([@bib47]). Phosphorylated c-Src was assessed using anti-phospho-Src (Tyr418) Antibody (1:100; Invitrogen Rabbit 44--660G). Secondary antibodies used were Alexa488 anti-Rat (1:500; Invitrogen Donkey A-21208) and Alexa555 anti-Rabbit (1:500; Donkey A-31572). Inflammatory cells were stained with anti-CD45 (1:300; BD Biosciences Goat 553076) and anti-CD68 (1:300; BioRad Rat MCA1957). Secondary antibodies used were Alexa488 anti-Rat (1:500; Invitrogen Donkey A-21208). Alexa555 anti-Goat (1:500; Invitrogen Donkey A-21432).

Immunofluorescent staining {#s4-5}
--------------------------

Whole mount immunostaining of retinas and choroids was performed following OIR and CNV experiments. Dissected issues, fixed in PFA were first incubated in blocking buffer (1% bovine serum albumin/2% fetal calf serum/0.05% Na-deoxycholate/0.5% Triton X-100/0.02% Na Azide in PBS) for 2 hr to block unspecific binding. Incubation with primary antibodies and secondary antibodies was carried out sequentially over night at 4°C on a rocking platform. Tissues were mounted on slides with Fluormount G mounting media (SouthernBiotech).

Microscopy was done using a Zeiss LSM700 microscope or a Leica SP8 confocal microscope. Images were acquired with the 20x, 40x or 63x objective. Processing and quantification of images was done with ImageJ software (NIH).

Quantification of avascular area and neovascular tufts {#s4-6}
------------------------------------------------------

Neovascular tuft formation and avascular area were determined by immunostaining retinas followed by image analysis. Quantification of total vascularized area, central avascular area, and tuft area was performed by outlining images manually in ImageJ. Using a tilescan of the IB4 channel for each whole mounted retina, the freehand selection tool was used to demarcate the vascular front, creating an ROI (region of interest) for the total vascularized area. The freehand selection tool was also used to outline IB4 positive vessels from neovascular tufts -- regions with disorganized dilated vessels often with markedly intense IB4 staining. The ROIs for tufts were merged into a single ROI corresponding to the all the neovascular tuft area for a given retina. The tuft area normalized to the total vascularized area was reported as a percentage of the total retina that contained tufts. Similarly, the avascular region was determined using the freehand selection tool to outline the central avascular regions. Regions where the superficial layer of capillaries was absent were determined and merged to form a single ROI corresponding to all of the avascular regions for a given retina. The avascular area normalized to the total vascularized area was reported as a percentage of the total retina that was still avascular. The researcher was blinded to the genotype of the sample when performing quantifications.

Quantification of fluorescent microspheres in CNV {#s4-7}
-------------------------------------------------

The quantity of extravasated fluorescent microspheres, marking sites of leakage, was measured in digital fluorescent images of CNV lesions from images taken with a Leica SP8 confocal microscope (63X objective) equipped with single and dual fluorescence filters charge-coupled device (CCD) camera. Camera settings were constant for images from all groups in each experiment. Using ImageJ software (NIH, Bethesda, MD), a guassian blur filter (sigma 1) was applied to each image and a threshold was applied to the microsphere channel (405 for Blue fluorescence) using the Triangle algorithm. Microsphere area was calculated using the Analyze Particles function with an upper limit of 500 pixels to avoid the inclusion of large staining artifacts.

Quantification of fluorescent microspheres in OIR {#s4-8}
-------------------------------------------------

For the OIR model, the quantity of extravasated fluorescent microspheres, marking sites of leakage, was measured in digital fluorescent images of regions of retina over 10 to 15 images in each eye taken with a Leica SP8 confocal microscope (63X objective) equipped with single and dual fluorescence filters charge-coupled device (CCD) camera. Camera settings were constant for images from all groups in each experiment. Using ImageJ software (NIH, Bethesda, MD), the microsphere channel and IB4-vessel channel (488 for Green fluorescence and 647 for IB4) were adjusted with threshold (Huang for Ib4 and Triangle for FITC) for each channel. Extravasated microsphere area was calculated by measuring the signal in the green fluorescence channel after removing any signal contained within the ROI (region of interest) corresponding to the IB4-positive area. The Analyze Particles function was employed to quantify the microspheres. A lower limit of 10 pixels was selected to distinguish the microsphere signal from background noise. The mean area density for each group of mice was calculated from the median value of all images of the eyes of each mouse ([@bib23]). To quantify leakage based on microscopic images, the amount of tracer extravasation was normalized to blood vessel density. The researcher was blinded to the genotype of the sample when performing quantifications.

Quantification of inflammatory cells in OIR {#s4-9}
-------------------------------------------

Immunostaining for CD68, CD45, and IB4 was performed on retinas from *Kdr^+/+^* and *Kdr^Y949F/Y949F^* mice. Confocal images were analyzed using ImageJ software for the presence of inflammatory cells within neovascular tufts. For each image, the tuft area was manually outlined using the freehand selection tool and then each channel was thresholded (CD68 with Zen; CD45 with Triangle) and the positive area within these tuft regions was calculated as the percentage of total tuft area. The average of five regions per retina are presented for each animal.

Statistical analysis {#s4-10}
--------------------

Statistical analysis was performed with GraphPad Prism (GraphPad). An unpaired Student's T test was used to compare means between experimental groups. A Mann Whitney U test was used to compare the medians between experimental groups with similar outcome. All tests were two-tailed and p\<0.05 was considered a statistically significant result. Values shown are the mean, with standard deviation used as the dispersion measure. Biological replicates refer to individual mice for OIR experiments and to individual lesions for CNV experiments. Independent experiments refer to experiments done in different days with independently generated material. A statistical method of sample size calculation was not used during study design. For in vivo experiments, we used an average of 6 animals per experiment, with a minimum of 3 (detailed number of animals used is given in figure legends). The investigators were blind to the genotype of the animal for data analysis.

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/501100000923Australian Research Council DE170100167 to Emma Gordon.

-   http://dx.doi.org/10.13039/501100004359Vetenskapsrådet 2015-02375 to Lena Claesson-Welsh.

-   http://dx.doi.org/10.13039/501100004063Knut och Alice Wallenbergs Stiftelse 2015.0030 to Lena Claesson-Welsh.

-   http://dx.doi.org/10.13039/501100004063Knut och Alice Wallenbergs Stiftelse 2015.0275 to Lena Claesson-Welsh.

-   http://dx.doi.org/10.13039/501100001674Fondation Leducq 17 CVD 03 to Lena Claesson-Welsh.

-   http://dx.doi.org/10.13039/501100004097Fondation ARC pour la Recherche sur le Cancer AIRC IG 18683 to Elisabetta Dejana.

We gratefully acknowledge the expert assistance of Marie Hedlund and Pernilla Martinsson, Uppsala University, and Monica Aronsson, St. Erik Eye Hospital. Critical input by Professor Mike Sapieha, University of Montreal, is gratefully acknowledged. Constructive discussions and advice from Fabrizio Orsenigo, IFOM, and Dr. Elisabet Ohlin Sjöström, SOBI, are much appreciated.

Additional information {#s5}
======================

No competing interests declared.

Conceptualization, Formal analysis, Investigation, Writing - original draft, Writing - review and editing.

Formal analysis, Investigation, Methodology, Writing - review and editing.

Conceptualization, Funding acquisition, Writing - review and editing.

Resources, Investigation, Writing - review and editing.

Resources, Funding acquisition, Writing - review and editing.

Resources, Writing - review and editing.

Resources, Writing - review and editing.

Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Writing - original draft, Writing - review and editing.

Animal experimentation: Mouse husbandry and oxygen-induced retinopathy (OIR) challenge took place at Uppsala University, and the University board of animal experimentation approved all animal work for those studies (Permit Number 5.8.18-06789-2018). Choroidal neovascularization (CNV) experiments took place at Karolinska Institutet, St. Erik Eye Hospital, Stockholm; the procedures were approved by the Stockholm\'s Committee for Ethical Animal Research (Permit Number Dnr 49/15). Animal handling was in accordance to the ARVO statement for the Use of Animals in Ophthalmologic and Vision Research.

Additional files {#s6}
================

Data availability {#s7}
=================

All data generated or analysed during this study are included in the manuscript and supporting files. Text files containing the ImageJ macros used for automatic detection of microspheres in Figures 1 and 2 are provided.

10.7554/eLife.54056.sa1

Decision letter

Bautch

Victoria L

Reviewing Editor

University of North Carolina, Chapel Hill

United States

Bautch

Victoria L

Reviewer

University of North Carolina, Chapel Hill

United States

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

This work analyzing the effects of a specific VEGFR2 phosphorylation (tyr949) on vascular permeability in vivo on oxygen-induced retinopathy to be interesting and timely, showing selective effects on vascular permeability. We also find that the revised manuscript has largely addressed the reviewer concerns, and we appreciate that you added the experimental numbers, clarified methods and analysis protocols, and added body weight data for the mice. These findings suggest that specific targeting of VEGFA signaling functions may provide therapeutic benefit in the future.

**Decision letter after peer review:**

Thank you for submitting your article \"Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Victoria L Bautch as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Jonathan Cooper as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript by Smith et al. investigates the mechanism whereby vascular leak is regulated during pathological retinal angiogenesis. They find that a specific phosphorylation site of VEGFR2 (Y949) is crucial for regulating leak in vivo, and show data that supports that Tsad, which binds to Y949, and specific phosphorylation of VE-cadherin on Y685, but not c-Src, are involved in the signaling to leak downstream of VEGFR2. The strengths of the study are the use of in vivo models and readouts that provide evidence that specific genetic manipulations lead to changes in leak, and the potential impact of the work in providing focus on a specific aspect of VEGFA signaling which could prevent the side effects associated with VEGFA therapy. The lack of differential c-Src phosphorylation may be due to the limitations of the reagents, as the antibodies are thought to cross-react with other Src family kinases. The limitations of the study are associated with the fact that phenotypes in vivo are more difficult to quantify. For example, the changes in pY685 VE-cadherin (Figure 3J) in the Y949 mutant background are significant but not robust; however, the actual mutant (VE-cadherin Y685F) shows a reduction in leak (Figure 4G). The major critique centers around better explanation and/or quantification of the phenotypes.

Essential revisions:

1\) Please address assay variability at several levels: Better explanation of quantification assays, and where appropriate increase the n of fields analyzed and/or mice used. Please use body weight to normalize for OIR (see below). Consider reanalysis of microsphere leak for those microspheres clearly outside the vessels.

a\) It would strengthen the work if the analysis protocols were more carefully explained. For example, the Materials and methods describe outlining to get areas of vascular, avascular, and tufts, but do not explain how areas where chosen for microsphere or antibody intensity analysis.

b\) Microsphere analysis -- it is a little difficult to interpret the overlay, but many of the spheres seem to be in or very near the tufts. Do the microspheres \"get stuck\" rather than wash out with the perfusion? It is also not clear how \"microsphere area\" is defined. It would strengthen the work to better define the quantification process, and perhaps to quantify the microspheres that are clearly not in the vessels. Likewise the quantification of the antibody intensity staining would benefit from more detail.

c\) For OIR model, the body weight of mouse pups should be reported, because pups with better postnatal weight gain have less neovessel formation in OIR (PMID: 21056995). In general, at least n=8-10 mice with 3 different litters are recommended to overcome biologic variability and obtain reliable readout from OIR model. Figure 4C-D (n=4-5 mice per group) of particular concern. Other data (Figures 1D, 2E, 4G would benefit from higher n, and n for animals and fields should be clearly stated in the figure legend).

2\) Tsad excision -- consider more rigorous quantification of the excision, perhaps by Western blot in the lungs, and association of excision and tufts: The authors provide 2 possible explanations for their findings that TSAD iECKO and WT have similar avascular areas: these include incomplete excision of Tsad and/or that some vessel regrowth is regulated upstream of TSAd in the Y949F mutant mice. The degree of excision of TSAd is shown in a supplementary figure -- some additional quantification by Western blot or some other method would be supportive and more convincing. Do the tuft regions have fewer recombined cells? This was not possible to distinguish in the figures provided.

3\) We request text edits to discuss possible adverse effects of targeting the Y949 of VEGFR2 in other physiological angiogenesis or VEGFR2-dependent processes.

10.7554/eLife.54056.sa2

Author response

> Essential revisions:
>
> 1\) Please address assay variability at several levels: Better explanation of quantification assays, and where appropriate increase the n of fields analyzed and/or mice used. Please use body weight to normalize for OIR (see below). Consider reanalysis of microsphere leak for those microspheres clearly outside the vessels.
>
> a\) It would strengthen the work if the analysis protocols were more carefully explained. For example, the Materials and methods describe outlining to get areas of vascular, avascular, and tufts, but do not explain how areas where chosen for microsphere or antibody intensity analysis.

We have now detailed how areas where chosen for microsphere and antibody intensity analysis in the Materials and methods section, in the Results section, and in the legends to Figures 2 and 4 (text marked in grey).

Microsphere analysis: The quantity of extravasated fluorescent microspheres, marking sites of leakage, was measured in digital fluorescent images of regions of retina over 10 to 15 images in each eye taken with a Leica SP8 confocal microscope (63X objective) equipped with single and dual fluorescence filters charge-coupled device (CCD) camera. Camera settings were constant for images from all groups in each experiment. Using ImageJ software (NIH, Bethesda, MD), the microsphere channel and IB4-vessel channel (488 for Green fluorescence and 647 for IB4) were adjusted with threshold (Huang for IB4 and Triangle for FITC) for each channel. Extravasated microsphere area was calculated by measuring the signal in the green fluorescence channel after removing any signal contained within the ROI (region of interest) corresponding to the IB4-positive area. The Analyze Particles function was employed to quantify the microspheres. A lower limit of 10 pixels was selected to distinguish the microsphere signal from background noise. The mean area density for each group of mice was calculated from the median value of all images of the eyes of each mouse. (see \[1\]. To quantify leakage based on microscopic images, the amount of tracer extravasation was normalized to blood vessel density. The researcher was blinded to the genotype of the sample when performing quantifications.

Antibody intensity i.e. neovascular tuft formation and avascular area: Neovascular tuft formation and avascular area were determined by immunostaining retinas followed by image analysis. Quantification of total vascularized area, central avascular area, and tuft area was performed by outlining images manually in ImageJ. Using a tilescan of the IB4 channel for each whole mounted retina, the freehand selection tool was used to demarcate the vascular front, creating an ROI (region of interest) for the total vascularized area. The freehand selection tool was also used to outline IB4-positive vessels from neovascular tufts -- regions with disorganized dilated vessels often with markedly intense IB4 staining. The ROIs for tufts were merged into a single ROI corresponding to the all the neovascular tuft area for a given retina. The tuft area normalized to the total vascularized area was reported as a percentage of the total retina that contained tufts. Similarly, the avascular region was determined using the freehand selection tool to outline the central avascular regions. Regions where the superficial layer of capillaries was absent were determined and merged to form a single ROI corresponding to all of the avascular regions for a given retina. The avascular area normalized to the total vascularized area was reported as a percentage of the total retina that was still avascular.

> b\) Microsphere analysis -- it is a little difficult to interpret the overlay, but many of the spheres seem to be in or very near the tufts. Do the microspheres \"get stuck\" rather than wash out with the perfusion? It is also not clear how \"microsphere area\" is defined. It would strengthen the work to better define the quantification process, and perhaps to quantify the microspheres that are clearly not in the vessels. Likewise the quantification of the antibody intensity staining would benefit from more detail.

We hope the response given above clarifies the methodology. In Figures 2D, 4G and Figure 4 --figure supplement G, we now show color-coded arrows to indicate extravasated microspheres. Red arrowheads indicate microspheres inside vessels while blue indicate microspheres outside vessels. Microspheres appearing to be on the vessel wall may be inside or outside; this cannot be distinguished. In this analysis, they have been counted as inside (see response to question "Do microspheres get stuck...").

> Do the microspheres \"get stuck\" rather than wash out with the perfusion?

It is quite likely that microspheres get stuck inside tufts perhaps due to the abnormal flow in these vessels. The microspheres may get stuck within the vessel or at the basement membrane. After perfusion (with 8 ml PBS), we can see remaining microspheres in tufts but never in normal vessels. For the analysis of OIR leakage, we therefore focus only on the clearly extravasated microspheres, away from the vessel wall, with any microsphere signal within the IB4 positive vessel area being removed. We have normalized the microsphere area to tuft area and therefore, the different tuft areas between wildtype and the various mutants we analyze do not affect the analyses. The difference between wildtype and mutants instead is due to that the mutants have stabilized junctions and therefore leak less. We have added a comment on the potential stickiness of the tuft vessel wall in the last paragraph of the subsection "Reduced vessel leakage from *Kdr^Y949F/Y949F^* retinopathy models".

> c\) For OIR model, the body weight of mouse pups should be reported, because pups with better postnatal weight gain have less neovessel formation in OIR (PMID: 21056995). In general, at least n=8-10 mice with 3 different litters are recommended to overcome biologic variability and obtain reliable readout from OIR model. Figure 4C-D (n=4-5 mice per group) of particular concern. Other data (Figures 1D, 2E, 4G would benefit from higher n, and n for animals and fields should be clearly stated in the figure legend).

We thank the reviewers for these comments which are well taken. We are aware of that the body weights influence the neovessel formation. We have now given the appropriate reference \[2\] (subsection "OIR"). Body weight of pups is given in Table 1.

Concerning the number of animals; we would like to emphasize that we have done many independent repeats. The litters that we generate from crossing of heterozygous recombinant animals are generally small (3-5 pups distributed in 25% wildtype, 50% heterozygous and 25% homozygous animals), and it may well be that we don't get any homozygous pups at all. Therefore, to have as many as 8-10 x 3 mice would require very many breeding couples over lengthy periods of time to obtain up to 30 litters with sufficient numbers of wildtype and mutant pups. To have 8-10 x 3 is feasible when working with adult mice where pairing of gender and age is more important than pairing litter mates, which is essential in the OIR model. However, we certainly do our best to follow Good Research Practice (defined as research of high quality, conducted and reported in a truthful way and with respect to important societal values, and that researchers take responsibility for their research and its consequences) and had continued to collect samples and also managed to have some more litters during the revision period. The n has now been increased for Figure 2B, C and E, Figure 3C and D, Figure 4D, E and G, and Figure 4---figure supplement 1H. As a result, the statistics is considerably improved. We thank the reviewers for this request.

The number of animals now is the following:

Figure 1: n is unchanged

Figure 2B, C: n is wt=10, Y949F=14 (was 8-11)

Figure 2E: n=6-7 (was 5-6)

Figure 3C, D: n=10-15 (was 8-11)

Figure 4D, E: VEC-WT n = 8 and for VEC-Y685F n = 11 (was 4-5).

Figure 4G: n=5-7 (was 3-5)

Figure 4---figure supplement 1H: n=5-6 (was 3-5)

> 2\) Tsad excision -- consider more rigorous quantification of the excision, perhaps by Western blot in the lungs, and association of excision and tufts: The authors provide 2 possible explanations for their findings that TSAD iECKO and WT have similar avascular areas: these include incomplete excision of Tsad and/or that some vessel regrowth is regulated upstream of TSAd in the Y949F mutant mice. The degree of excision of TSAd is shown in a supplementary figure -- some additional quantification by Western blot or some other method would be supportive and more convincing. Do the tuft regions have fewer recombined cells? This was not possible to distinguish in the figures provided.

The tuft regions have a similar distribution of recombined cells as the rest of the retina. We have given a comment on this fact in the subsection "pY949 signaling axis results in altered VE-cadherin phosphorylation".

In Gordon et al., \[3\], Figure 3---figure supplement 1B, we provide extensive blotting data on the degree of excision of Tsad in the tamoxifen-treated *Tsad^fl/fl^;Cdh5-CreERT2* mice (about 80%). We used lung lysates for VEGFR2 ip and TSAd blot to specifically analyze excision in endothelial cells. We now refer to the Gordon et al., paper in the subsection "pY949 signaling axis results in altered VE-cadherin phosphorylation".

Due to problems with generating sufficient number of *Tsad^fl/fl^* animals of the right genotype to redo the blotting exercise (which is always difficult for technical reasons, poor antibodies etc.), we don't show this again in this paper.

Finally, with the increased n, there is no longer a significant difference in avascular area between the *Vegfr2^Y949F/Y949F^* and its wildtype and therefore, there is no longer a need to comment on *Vegfr2^Y949F/Y949F^* vis-a-vis the similar avascular area for the *Tsad^fl/fl^* strain and its wildtype. Those comments in the text have been removed.

> 3\) We request text edits to discuss possible adverse effects of targeting the Y949 of VEGFR2 in other physiological angiogenesis or VEGFR2-dependent processes.

We have shown that the *Vegfr2^Y949F/Y949F^*mouse exhibits reduced metastatic spread \[4\], improved heart function after myocardial infarction (Li et al., submitted) and in the current paper, reduced pathological angiogenesis and leakage in retinopathy models. To what extent the VEGFA-regulated vascular barrier contributes to physiology has remained an enigma. Developmental angiogenesis is unaffected by the improved barrier in the Y949F mouse \[4\]. It remains to be tested whether wound healing or bacterial infections are affected. However, now, we studied the extent of inflammatory cell infiltration in the wildtype and *Vegfr2^Y949F/Y949F^* strains. There was no difference in the degree of CD68+ and CD45+ cell infiltration. These data have been added in a new Figure 2---figure supplement 2. We comment on this result in the subsection "Reduced vessel leakage from *Kdr^Y949F/Y949F^*retinopathy models" and in the Discussion, stating that inflammatory cell infiltration is not affected by the improved junction stability in the *Vegfr2^Y949F/Y949F^* strain. These results suggest that the improved vascular barrier in the strains studied here preferentially acts to suppress molecular leakage. Moreover, we describe the lack of understanding on the role of vascular barrier stability to VEGFA-induced molecular leakage in physiology. See the Discussion.
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